BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17914733)

  • 1. Initial testing of dasatinib by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1190-7. PubMed ID: 18260118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jul; 51(1):42-8. PubMed ID: 18293383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
    Keir ST; Maris JM; Lock R; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2010 Dec; 55(6):1126-33. PubMed ID: 20672370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
    Lock R; Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1181-9. PubMed ID: 18085673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial testing of cisplatin by the pediatric preclinical testing program.
    Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
    Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
    Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.
    Gorlick R; Maris JM; Houghton PJ; Lock R; Carol H; Kurmasheva RT; Kolb EA; Keir ST; Reynolds CP; Kang MH; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Sep; 59(3):518-24. PubMed ID: 22102563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
    Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
    Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
    Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
    Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2014; 201():27-65. PubMed ID: 24756784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.